Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Endocrinological Investigation
Published in: Journal of Endocrinological Investigation 5/2008

01-05-2008 | Original Articles

Sustainability of a well-monitored salt iodization program in Iran: Marked reduction in goiter prevalence and eventual normalization of urinary iodine concentrations without alteration in iodine content of salt

Authors: F. Azizi, MD, L. Mehran, R. Sheikholeslam, A. Ordookhani, M. Naghavi, M. Hedayati, M. Padyab, P. Mirmiran

Published in: Journal of Endocrinological Investigation | Issue 5/2008

Login to get access
Metadata
Title
Sustainability of a well-monitored salt iodization program in Iran: Marked reduction in goiter prevalence and eventual normalization of urinary iodine concentrations without alteration in iodine content of salt
Authors
F. Azizi, MD
L. Mehran
R. Sheikholeslam
A. Ordookhani
M. Naghavi
M. Hedayati
M. Padyab
P. Mirmiran
Publication date
01-05-2008
Publisher
Springer International Publishing
Published in
Journal of Endocrinological Investigation / Issue 5/2008
Electronic ISSN: 1720-8386
DOI
https://doi.org/10.1007/BF03346386

Other articles of this Issue 5/2008

Journal of Endocrinological Investigation 5/2008 Go to the issue

Opinion

Lessons from second- and third-generation parathyroid hormone assays in primary hyperparathyroidism

Opinion

Lessons from a second- and third-generation parathyroid hormone assays in renal failure patients

Original Articles

Normal age-dependent values of serum insulin growth factor-I: Results from a healthy Italian population

Original Articles

Menarcheal age in celiac disease may not be delayed and may be irrespective of age at diagnosis and dietary management

Review Article

Pharmacy and pharmacology of biosimilars

Original Articles

Biochemical markers for cardiovascular risk following treatment in endogenous Cushing’s syndrome
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits